Forging a potent vaccine adjuvant: CpG ODN/cationic peptide nanorings

Type I interferon inducers may potentially be engineered to function as antiviral and anticancer agents, or alternatively, vaccine adjuvants, all of which may have clinical applications. We recently described a simple strategy to convert a Toll-like receptor 9 (TLR9) agonist devoid of interferon α (...

Descripción completa

Detalles Bibliográficos
Autores principales: Gungor, Bilgi, Yagci, Fuat Cem, Gursel, Ihsan, Gursel, Mayda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4292235/
https://www.ncbi.nlm.nih.gov/pubmed/25610738
http://dx.doi.org/10.4161/21624011.2014.950166
Descripción
Sumario:Type I interferon inducers may potentially be engineered to function as antiviral and anticancer agents, or alternatively, vaccine adjuvants, all of which may have clinical applications. We recently described a simple strategy to convert a Toll-like receptor 9 (TLR9) agonist devoid of interferon α (IFNα) stimulating activity into a robust Type I interferon inducer with potent vaccine adjuvant activity.

Ejemplares similares